NASDAQ: PRFXPainreform Ltd Stock
$0.50+0.03 (+6.38%)
Updated Jun 5, 2023
PRFX Price
$0.50
Fair Value Price
$1.13
Market Cap
$5.36M
52 Week Low
$0.34
52 Week High
$1.29
P/E
-0.57x
P/B
0.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$7M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRFX Overview
PainReform Ltd. develops reformulations of established pain therapeutics. Its PRF-110 product is a viscous clear oil-based solution instilled directly into surgical wounds to provide localized and extended post-operative analgesia. PRF-110 is in clinical trials related to bunionectomy surgeries and hernia repairs. PainReform was incorporated in 2007 and is headquartered in Tel Aviv, Israel.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRFX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRFX ($0.50) is undervalued by 55.77% relative to our estimate of its Fair Value price of $1.13 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PRFX ($0.50) is significantly undervalued by 55.77% relative to our estimate of its Fair Value price of $1.13 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PRFX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRFX due diligence checks available for Premium users.
Be the first to know about important PRFX news, forecast changes, insider trades & much more!
PRFX News
Valuation
PRFX fair value
Fair Value of PRFX stock based on Discounted Cash Flow (DCF)
Price
$0.50
Fair Value
$1.13
Undervalued by
55.77%
PRFX ($0.50) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRFX ($0.50) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRFX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRFX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.57x
Industry
14.98x
Market
53.21x
PRFX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
1.78x
PRFX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRFX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
PRFX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.4M
Liabilities
$1.5M
Debt to equity
0.17
PRFX's short-term assets ($10.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRFX's short-term assets ($10.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRFX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$6.0M
Financing
$0.0
PRFX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRFX vs Pharmaceutical Stocks
Painreform Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.